NDA 215487 · Scienture
Rezenopy
Naloxone Hydrochloride · Nasal
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Apr 19, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
682
129 Phase 3, 31 recruiting
FAERS reports
809
510 serious, 100 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 3, 2026.
REZENOPY nasal spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. REZENOPY nasal spray is not a substitute for emergency medical care. REZENOPY nasal spray is an opioid antagonist for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ( 1 ) REZENOPY nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. ( 1 ) REZENOPY nasal spray is not a substitute for emergency medical care. ( 1 )
Mechanism: Naloxone hydrochloride is an opioid antagonist that antagonizes opioid effects by competing for the same receptor sites. Naloxone hydrochloride reverses the effects of opioids, including respiratory depression, sedation, and hypotension. It can also reverse the psychotomimetic and dysphoric effects of agonist-antagonists such as pentazocine.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- REZENOPY · NALOXONE HYDROCHLORIDE 10MG/SPRAY · SPRAY, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Naloxone" as an intervention, any sponsor and status, largest first.
- Houston Emergency Opioid Engagement SystemEnrolling by invitation
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03396276 · 3,000 participants (planned) · Start Apr 1, 2018 · Primary completion Aug 31, 2030
Drug: Suboxone · For: Opioid Use Disorder
Sites: Houston, Texas
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)Pivotal-lookingActive, not recruiting
NYU Langone HealthAcademic, hospital or other
NCT04464980 · 1,516 participants · Start Jun 8, 2021 · Primary completion Dec 31, 2026
Drug: SL-BUP; XR-BUP and 1 more · For: Opioid Use Disorder (OUD)
Sites: Little Rock, Arkansas; Tarzana, California; Bridgeport, Connecticut · 21 sites in all
- Naloxone HCl PR Tablets in Patients With Opioid Induced ConstipationPivotal-lookingStatus unknown
Develco Pharma Schweiz AGIndustry
NCT03687268 · 1,500 participants (planned) · Start Jul 31, 2017 · Primary completion Nov 2019
Drug: Naloxone HCl PR tablets; Placebo Oral Tablet · For: Opioid-Induced Constipation
Sites: Plovdiv, Bulgaria; Sevlievo, Bulgaria; Sofia, Bulgaria · 104 sites in all
- COMBINE (Acamprosate/Naltrexone)Pivotal-lookingCompleted
University of North Carolina, Chapel HillAcademic, hospital or other
NCT00006206 · 1,375 participants · Start Aug 1997
Drug: naltrexone (Revia); acamprosate (Campral) · For: Alcoholism
Sites: New Haven, Connecticut; Miami, Florida; Belmont, Massachusetts · 12 sites in all
- The Study of Brave-LC LDN Treatment TrialPivotal-lookingNot yet recruiting
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT07916259 · 1,300 participants (planned) · Start Nov 16, 2026 · Primary completion Dec 31, 2028
Drug: naltrexone · For: Post-acute COVID-19 Syndrome
Sites: Birmingham, Alabama; Chula Vista, California; Denver, Colorado · 13 sites in all
- Starting Treatment With Agonist Replacement Therapies (START)Pivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT00315341 · 1,269 participants · Start Apr 2006 · Primary completion Aug 2010
Drug: Buprenorphine/naloxone; Methadone · For: Opiate-related Disorders
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 9 sites in all
- Drug Treatment Combined With Drug and Risk Reduction Counseling to Prevent of HIV Infection and Death Among Injection Drug UsersPivotal-lookingTerminated
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00270257 · 1,251 participants · Start May 2008 · Primary completion Jul 2012
Drug: Buprenorphine/Naloxone · For: HIV Infections; Opioid-Related Disorders
Sites: Hengzhou Town, China; Nanning, China; Ürümqi, China · 4 sites in all
- Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back PainPivotal-lookingCompleted
Purdue Pharma LPIndustry
NCT01358526 · 1,095 participants · Start May 2011 · Primary completion Oct 2012
Drug: Oxycodone/Naloxone Controlled-release; Placebo · For: Low Back Pain
Sites: Birmingham, Alabama; Haleyville, Alabama; Huntsville, Alabama · 151 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue90
- nausea73
- headache54
- drug ineffective52
- diarrhoea51
- off label use50
- pain50
- death47
- dyspnoea47
- product dose omission issue46
- asthenia37
- rash36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 6 |
| 2011 | 5 |
| 2012 | 15 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 10 |
| 2017 | 19 |
| 2018 | 35 |
| 2019 | 41 |
| 2020 | 49 |
| 2021 | 28 |
| 2022 | 58 |
| 2023 | 120 |
| 2024 | 128 |
| 2025 | 157 |
| 2026 | 119 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
Kistemaker KRJ, Sijani F, Brinkman DJ, et al. · Cancer Treat Rev 2024 · Meta-Analysis, Systematic Review
- Naloxone for shock.
Boeuf B, Poirier V, Gauvin F, et al. · Cochrane Database Syst Rev 2003 · Meta-Analysis, Systematic Review
- Naloxone for opioid-exposed newborn infants.
Moe-Byrne T, Brown JVE, McGuire W · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis.
Fischer LS, Asher A, Stein R, et al. · BMC Public Health 2025 · Systematic Review, Meta-Analysis
- Opioid antagonists for smoking cessation.
David S, Lancaster T, Stead LF, et al. · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Huhn AS, Finan PH, Gamaldo CE, et al. · Sci Transl Med 2022 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Scienture
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.